Jump to start of content

Complete requirements by 12/31/18 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/18 could result in a change to your certification status.

Breadcrumb trail:

Rheumatology Board

Expand All | Collapse All

Marcy B. Bolster, MD, Chair

Marcy B. Bolster, MDDr. Bolster is an Associate Professor of Medicine at Harvard Medical School. She is the Director of the rheumatology fellowship training program in the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital (MGH). She is a board certified rheumatologist.

Prior to her position at MGH, she was a Professor of Medicine, Division of Rheumatology, at the Medical University of South Carolina (MUSC), where she was on the faculty from 1993-2012. She also served as the Director of the rheumatology fellowship training program, the Medical Director of the Center for Osteoporosis and Bone Health and the Medical Director of the Musculoskeletal Institute at MUSC.

She is a fellow of the American College of Physicians and of the American College of Rheumatology (ACR), a member of the International Society for Clinical Densitometry and a member of the American Society for Bone Mineral Research. She is Chair, ACR Committee on Training and Workforce (COTW). She has served as co-leader for the ACR in the ACGME Next Accreditation System. She is a member of both the ACR and the Rheumatology Research Foundation Boards of Directors. She has served on the American Board of Internal Medicine (ABIM) Rheumatology Board and is currently its Chair. She is also the Chair of the ABIM Rheumatology Board Exam Committee, serves as a member of the ABIM Council and is the Chair of the ABIM Exam Chairs Committee. She is a member of the MGH Department of Medicine Education Council and Innovation in Education Committee. She previously served as the co-Chairperson for the ACR Rheumatology In-Training Examination and on the ACR COTW, chairing the Sub-Committee on Resident Education, spearheading the development of “Rheum2Learn,” an online internal medicine resident education tool for rheumatology.

She obtained a bachelor of arts degree in chemistry and her medical degree from Duke University. She trained in internal medicine at the Eastern Virginia Graduate School of Medicine and obtained rheumatology training at MUSC.

As of January 2017, Dr. Bolster reported the following external relationships:

Clinical research, with funding for clinical trial expenses, clinical research staff and salary support, paid to Brigham and Women's Hospital and Massachusetts General Hospital, from the following company:

  • Eli Lilly & Co., to study the use of teriparatide in patients with rheumatoid arthritis to determine if it might help improve erosions.

Work funded by educational grants from industry, paid directly to Massachusetts General Hospital Rheumatology, from the following companies:

  • AbbVie, providing partial salary support for a rheumatology fellow; funding is used solely for a fellow's salary support.
  • Amgen, providing partial salary support for a rheumatology fellow through the Rheumatology Research Foundation; funding is used solely for a fellow's salary support.

Work as an author or editor for following companies, with compensation as listed below:

  • Elsevier, receiving compensation as an editor for a volume of Rheumatic Disease Clinics of North America: Corticosteroids.
  • Merck Manual, receiving compensation as an author.

Atulya A. Deodhar, MD

Dr. Deodhar, a board certified internist and rheumatologist, is Professor of Medicine and Medical Director of rheumatology clinics at the Division of Arthritis & Rheumatic Diseases in Oregon Health & Science University, Portland. He is a fellow of the American College of Rheumatology (ACR) and the American College of Physicians.

Dr. Deodhar is the Chairman of SPARTAN (Spondyloarthritis Research and Treatment Network), an organization of North American rheumatologists dedicated to education and research in the field of axial spondyloarthritis. He serves on the ACR's treatment guidelines subcommittee and has served in the past as a member and Vice Chair of the Annual Meeting Planning Committee and as a member of the Peripheral MRI Task Force. Dr. Deodhar also served on the Association of Rheumatology Health Professionals (ARHP) nominating committee. Additionally, he serves as a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Deodhar is a reviewer for Arthritis & Rheumatology, Annals of the Rheumatic Diseases and Annals of Internal Medicine, among several other journals. His research interests are axial spondyloarthritis and psoriatic arthritis. He has authored three books, more than 100 peer-reviewed articles, several book chapters, and editorials. Dr. Deodhar has been a principal or co-investigator in more than 100 clinical trials, mainly focused on therapies for ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis.

He completed his fellowship in rheumatology at Oregon Health & Science University, and before that, a research fellowship in rheumatology at the Royal Cornwall Hospital, Truro, England. He completed his residency in internal medicine and geriatrics at the Royal Cornwall Hospital, Truro, as well as in the Sassoon General Hospital and King Edward Memorial Hospital, Pune, India. Dr. Deodhar received his bachelor's degree in medicine and surgery and his medical degree from the University of Pune, India, and his membership of the Royal College of Physicians, London, England.

As of January 2017, Dr. Deodhar reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to Oregon Health and Science University, from the following companies:

  • Eli Lilly and Company, funding work as Principal Investigator for a study of ixekizumab in the treatment of axial spondyloarthritis.
  • GlaxoSmithKline, funding work as Principal Investigator for a trial of belimumab in the treatment of antineutrophil cytoplasmic autoantibodies (ANCA) -associated vasculitis.
  • Novartis, funding work as Principal Investigator for trials of secukinumab in the treatment of non-radiographic axial spondylarthritis and psoriatic arthritis.
  • Pfizer, funding work as Principal Investigator for a trial of etanercept in the treatment of non-radiographic axial spondyloarthritis.
  • UCB, funding work as Principal Investigator for a trial of certolizumab in the treatment of non-radiographic axial spondyloarthritis.

Investigators' meetings for the following companies, with compensation as listed:

  • Eli Lilly and Company, meeting to consult on research studies of ixekizumab and baricitinib in axial spondyloarthritis, receiving honoraria.
  • Janssen, clinical research protocol discussion meeting regarding three different trials - in ankylosing spondylitis, and non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • Novartis, research meeting related to trials of secukinumab in non-radiographic axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.
  • UCB, teleconferences regarding the study of non-radiographic axial spondyloarthritis, receiving honoraria.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Eli Lilly and Company, to discuss results of research studies of ixekizumab in psoriatic arthritis, receiving reimbursement for travel expenses and honoraria.
  • Janssen, to discuss trial design and progress of the clinical trial on guselkumab in the treatment of psoriatic arthritis, receiving reimbursement for travel expenses and honoraria.
  • Novartis, to discuss the clinical trial design for secukinumab in the treatment of non-radiographic axial spondyloarthritis, and to discuss the future of targeted therapies, receiving reimbursement for travel expenses and honoraria.
  • Pfizer, to discuss the ongoing trial of etanercept in non-radiographic axial spondyloarthritis,, receiving reimbursement for travel expenses and honoraria.
  • UCB, to discuss the drugs certolizumab and bimekizumab and the future landscape of treatments for axial spondyloarthritis, receiving reimbursement for travel expenses and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation as listed:

  • Eli Lilly and Company, providing advice on a clinical trial protocol for the use of baricitinib in ankylosing spondylitis, receiving honoraria.
  • Novartis, to consult on the design of a clinical trial and to advise on preparation for appearing before the U.S. Food and Drug Administration, receiving reimbursement for travel expenses and honoraria.

Industry-supported continuing medical education supported by the following companies, with compensation for travel expenses and honoraria:

Dr. Deodhar serves as faculty for educational symposia on axial spondyloarthritis and psoriatic arthritis, conducted by the SpondyloArthritis Research and Treatment Network (SPARTAN) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). CME credits are provided by Oregon Health & Science University, with pooled funding provided by multiple pharmaceutical companies, including AbbVie, Amgen, Crescendo Pharmaceuticals, Janssen, Novartis, Pfizer and UCB.

Dr. Deodhar also serves as a discussant for Medscape, providing commentary on abstracts presented at the American College of Rheumatology, receiving reimbursement for travel expenses and honoraria.

Dr. Deodhar serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Rheumatology, Member of Treatment Guidelines Subcommittee, and Core Member, Treatment Guidelines for Axial Spondyloarthritis, receiving reimbursement for travel expenses.
  • Spondyloarthritis Research and Treatment Network (SPARTAN), Chair of a non-profit organization dedicated to stimulate research and education in the field of spondyloarthritis.

Elana R. Eisner, MD

Dr. Eisner is a board certified internist and rheumatologist. She is currently in private practice at Rheumatic Disease Associates in Willow Grove, Pennsylvania.

Currently, Dr. Eisner serves as a member of the American Board of Internal Medicine Rheumatology Board. She is also a Board Member of the Philadelphia Rheumatism Society. Dr. Eisner is involved in the teaching of internal medicine residents at Abington Memorial Hospital. She is also an instructor to the rheumatology fellows at Drexel University School of Medicine.

Dr. Eisner earned her medical degree from the University of Pennsylvania School of Medicine. She did her residency and rheumatology fellowship at the Hospital of the University of Pennsylvania.

As of January 2017, Dr. Eisner reported the following external relationships:

Dr. Eisner serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Philadelphia Rheumatism Society, President, without compensation.

Dr. Eisener is a member of the Ultrasound School of North American Rheumatologists and serves as a volunteer to grade musculoskeletal ultrasounds performed by trainees, without compensation.

Carlos M. Gadea MD

Dr. Gadea is a rheumatologist at the University of Alabama at Birmingham (UAB) Medicine Multispecialty Clinic at Baptist Medical Center South in Montgomery, Alabama. As a clinical instructor, he works with internal medicine residents from the UAB-Montgomery Internal Medicine residency program on their rheumatology elective rotation. He is board certified in both Internal Medicine and Rheumatology.

Prior to his work at UAB, Dr. Gadea worked in a small private rheumatology practice in Seaford, Delaware, with two other rheumatologists. Before that, Dr. Gadea practiced in Pittsburgh, Pennsylvania, at the University of Pittsburgh Medical Center (UPMC). As a Clinical Instructor for the UPMC Division of Rheumatology, he worked as a rheumatologist in one of the division’s satellite rheumatology clinics caring for patients, and providing consultation at St. Clair Hospital and UPMC Mercy, where he also worked with internal medicine residents. After fellowship training, he practiced with a private rheumatology group with four other rheumatologists in Virginia Beach, Virginia.

Dr. Gadea is a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Gadea received his bachelor’s degree in biological sciences from Florida International University. He earned his medical degree from Universidad de Ciencias Medicas de Centro America in San Jose, Costa Rica. He completed his internal medicine residency training with the University of Connecticut Primary Care Internal Medicine program in Farmington, Connecticut, and his rheumatology fellowship at the University of Kentucky in Lexington, Kentucky.

As of January 2018, Dr. Gadea reported no external relationships.

Salahuddin Kazi, MD

Dr. Kazi, a board certified internist and rheumatologist, is the Vice Chair of Education for the Department of Internal Medicine and an Associate Professor of Medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center in Dallas, Texas. He is also the Director of the Internal Medicine Residency Training Program at UT Southwestern.

Dr. Kazi is a member of the American Board of Internal Medicine Rheumatology Board.

Dr. Kazi earned his medical degree from Dow Medical College in Karachi, Pakistan, and completed his residency and chief residency in internal medicine and fellowship in rheumatology at the University of Texas-Medical School at Houston.

As of March 2018, Dr. Kazi reported the following external relationships:

Dr. Kazi serves as a faculty member, Rheumatology content expert, and IT liaison for the Dartmouth Institute for Health Policy and Clinical Practice, with compensation paid to the University of Texas Southwestern Medical Center.

Kristine M. Lohr, MD

Dr. Lohr, board certified in Rheumatology, is Professor of Medicine, Director of the Rheumatology Fellowship Program, and Interim Chief of the Division of Rheumatology in the Department of Medicine at the University of Kentucky in Lexington, Kentucky.

Previously, as a faculty member of The University of Tennessee Health Science Center (UTHSC) College of Medicine, she served as Director of two courses (Pathophysiology and Introduction to Clinical Skills) before becoming Associate Dean for Outcomes Research and Improvement. As Associate Dean, she developed and co-directed the Patient Safety/Quality Improvement Clerkship. She began her academic career as an Assistant Professor of Medicine at The Medical College of Wisconsin.

Dr. Lohr served as co-Chair for the American College of Rheumatology (ACR) Annual Review Course. She is currently a member of the ACR Committee on Workforce and Training and the ACR Annual Meeting Planning Committee. She is also a Board Member of Rheumatology Network and represents the ACR as a Board Member of the United States Bone and Joint Initiative. Dr. Lohr received the ACR Clinician Scholar Educator Award while at UTHSC, and was a fellow of the Hedwig van Ameringen Executive Leadership in Academic Medicine Program at Allegheny University for the Health Sciences (now Drexel University College of Medicine). She is currently a member of the American Board of Internal Medicine (ABIM) Rheumatology Board and was formerly a member of the ABIM Rheumatology Board Exam Committee. Her academic career has centered on undergraduate and graduate medical education.

Dr. Lohr earned her medical degree at the University of Rochester School of Medicine and Dentistry. She did her residency in the Department of Medicine at The Ohio State University Hospital and fellowship training in rheumatology at Duke University Medical Center.

As of January 2017, Dr. Lohr reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Kentucky, from the following company:

  • Takeda, for a study evaluating the cardiovascular safety and efficacy of febuxostat and allopurinol in subjects with cardiovascular comorbidities, hyperuricemia and gout.

Dr. Lohr serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Rheumatology, Member of the Annual Meeting Planning Committee, receiving reimbursement for travel expenses and registration for the annual meeting; Member of the Workforce and Training Committee, receiving reimbursement for travel expenses; Member of Audiovisual Aids Subcommittee, receiving reimbursement for travel expenses.
  • United States Bone and Joint Initiative, serving as the American College of Rheumatology representative to their Board of Directors, receiving reimbursement for travel expenses.

Dr. Lohr serves on the Rheumatology Network Board, and as a member of the Editorial Board, with honoraria paid to the University of Kentucky.

Joan F. Meissner, JD

Ms. Meissner is Assistant General Counsel at BeiGene, a biopharmaceutical company dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

Previously, Ms. Meissner worked at ARIAD Pharmaceuticals, progressing from Corporate Counsel to Assistant General Counsel for more than 12 years as ARIAD transitioned from a research and development company to a multi-national commercial company with two oncology products. She started her legal career as a corporate associate at Ropes & Gray in Boston, following a clerkship with the Supreme Judicial Court of Massachusetts.

Ms. Meissner serves as a member of the American Board of Internal Medicine Rheumatology Board. Additionally, she is a member of the Board of Directors of the Scleroderma Foundation of New England.

Ms. Meissner received a Juris Doctorate from Boston College Law School and a bachelor's degree in English and psychology from the University of Notre Dame.

As of March 2018, Ms. Meissner reported the following external relationships:

Ms. Meissner serves in significant role with the following organization, receiving reimbursement or compensation as listed:

  • Scleroderma Foundation of New England, Board Member, without compensation.

She also reported that as an attorney, she is currently consulting for two pharmaceutical companies, BeiGene, Ltd. and Takeda Pharmaceucticals.

Benjamin Smith, PA-C

Mr. Smith is the Academic Coordinator and Teaching Faculty I at the Florida State University College of Medicine School of Physician Assistant Practice in Tallahassee, Florida. He practices clinically as a Physician Assistant in rheumatology at the McIntosh Clinic, P.C., in Thomasville, Georgia. He works with his supervising physician, Victor M. McMillan, MD, FACP, FACR. He is certified by the National Commission on Certification of Physician Assistants.

Currently, Mr. Smith serves on the American Board of Internal Medicine Rheumatology Board. He is the Scientific Editor of the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Rheumatology e-Bytes, an online educational tool presently in development. Mr. Smith was elected the 43rd ARHP President in 2011, the first physician assistant to serve in this capacity. He is the first ARHP member to serve on the ACR Executive Committee. Additionally, Mr. Smith has served on numerous other ACR/ARHP committees and task forces, primarily with a focus on education. He is a Distinguished Fellow of the American Academy of Physician Assistants (AAPA) and currently serves as the Chair of the AAPA Commission on Continuing Professional Development and Education.

Mr. Smith received a bachelor's degree in biology from the University of Georgia, graduating cum laude, and his physician assistant degree from the Medical College of Georgia, graduating summa cum laude.

As of January 2017, Mr. Smith reported the following external relationships:

Mr. Smith serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Academy of Physician Assistants, serving as Chair of the Commission on Continuing Professional Development and Education, receiving reimbursement for travel expenses and honoraria.
  • Association of Rheumatology Health Professionals, serving as Scientific Editor for eBytes, receiving honoraria.
  • Georgia Association of Physician Assistants, Conference Speaker, receiving reimbursement for travel expenses and honoraria.